Nyxoah (NYXH) Cash from Financing Activities (2021 - 2026)
Nyxoah (NYXH) recorded quarterly Cash from Financing Activities of $468298.3 in Q1 2026, down 39.01% quarter-over-quarter from $767875.6 in Q1 2025, and down 39.01% on a YoY basis from $767875.6 in Q1 2025.
Nyxoah (NYXH) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Nyxoah's Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $468298.3 for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 39.01% year-over-year to $468298.3; the TTM figure through Mar 2026 stood at $36.2 million (down 56.86% YoY), while the FY2025 annual figure was $44.4 million, down 46.4% from the prior year.
- Cash from Financing Activities was $468298.3 for Q1 2026 at Nyxoah, down from $767875.6 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $48.2 million in Q2 2024 to a low of -$772524.9 in Q4 2023.
- Historically, Cash from Financing Activities has averaged $7.3 million across 5 years, with a median of $371573.9 in 2024.
- Biggest YoY gain for Cash from Financing Activities was 9839.52% in 2023; the steepest drop was 245.75% in 2023.
- A 5-year view of Cash from Financing Activities shows it stood at -$223434.2 in 2022, then slumped by 245.75% to -$772524.9 in 2023, then soared by 3333.35% to $25.0 million in 2024, then plunged by 96.93% to $767875.6 in 2025, then slumped by 39.01% to $468298.3 in 2026.
- The last three Cash from Financing Activities figures came in at $468298.3 (Q1 2026), $767875.6 (Q1 2025), and $25.0 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | -1.35 Bn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | -414.00 Mn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | -13.00 Mn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | -255.24 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | -308.70 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | -50.00 Mn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | -75.80 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | -48.13 Mn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | -11.00 Mn |
| 10 | Nyxoah | 0.69 | 0.69 | 4.26 Mn | 468,298.26 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 468,298.26 |
| Mar 31, 2026 | 468,298.26 |
| Mar 31, 2025 | 767,875.64 |
| Mar 31, 2025 | 767,875.64 |
| Dec 31, 2024 | 24.98 Mn |
| Dec 31, 2024 | 24.98 Mn |
| Sep 30, 2024 | 9.98 Mn |
| Sep 30, 2024 | 9.98 Mn |
| Jun 30, 2024 | 48.17 Mn |
| Jun 30, 2024 | 48.17 Mn |
| Mar 31, 2024 | 274,849.53 |
| Mar 31, 2024 | 274,849.53 |
| Dec 31, 2023 | -772,524.85 |
| Dec 31, 2023 | -772,524.85 |
| Sep 30, 2023 | -239,489.90 |
| Sep 30, 2023 | -239,489.90 |
| Jun 30, 2023 | 2.63 Mn |
| Jun 30, 2023 | 2.63 Mn |
| Mar 31, 2023 | 16.51 Mn |
| Mar 31, 2023 | 16.51 Mn |